Progressive Multifocal Leukoencephalopathy Treatment Market

Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot (2023 to 2033)

The global progressive multifocal leukoencephalopathy treatment market is expected to garner a market value of USD 1,320 million in 2023 and is expected to accumulate a market value of USD 1,773.97 million by registering a CAGR of 3% in the forecast period 2023 to 2033. The market for progressive multifocal leukoencephalopathy treatment registered a CAGR of 2% in the historical period 2018 to 2022.

The progressive multifocal leukoencephalopathy treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The progressive multifocal leukoencephalopathy treatment market offers a range of products and services for its effective management and treatment such as corticosteroids, such as prednisone, antiviral medications, such as cidofovir, Immunoglobulin therapy, and immunomodulatory treatments, such as interferon.

Data Points	Key Statistics
Expected Market Value (2023)	USD 1,320 million
Anticipated Forecast Value (2033)	USD 1,773.97 million
Projected Growth Rate (2023 to 2033)	3% CAGR

2018 to 2022 Progressive Multifocal Leukoencephalopathy Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for progressive multifocal leukoencephalopathy treatment reflected a value of 2% during the historical period, 2018 to 2022.

The market for Progressive Multifocal Leukoencephalopathy Treatment is gaining prominence as it is considered a rare, life-threatening brain disease caused by the JC virus. Furthermore, due to the rarity of the disease, there is ongoing research into developing new treatments for PML, expected to drive demand for these treatments.

The development of new PML treatments is a high priority for the medical community due to the devastating effects of the disease and the limited treatment options available. As more effective treatments become available, the market for PML treatment is likely to grow. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Progressive Multifocal Leukoencephalopathy Treatments is fuelling the market growth. Thus, the market for progressive multifocal leukoencephalopathy treatment is expected to register a CAGR of 3% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Progressive Multifocal Leukoencephalopathy Treatment Market?

Growing advancements in diagnostic and treatment options to push the market growth

The global market for progressive multifocal leukoencephalopathy treatment is primarily driven by the incidence of blood cancers, including multiple myeloma, the development of new and effective treatment options, advancements in treatment technologies and development of new diagnostic technologies and the availability of more effective treatments. According to the latest studies, PML occurs in approximately one in 200,000 people. As per the same report, each year, it is estimated that 4,000 people develop PML in the United States and Europe combined.

The growth of the progressive multifocal leukoencephalopathy treatment market is owed to the increasing prevalence of the condition owing to the increasing use of immunosuppressive drugs for autoimmune and other conditions. As a result, the players in the market are working on the development of new diagnostic tools and imaging techniques that are likely to improve the accuracy of Progressive Multifocal Leukoencephalopathy diagnosis.

For instance, in November 2021, Japan approved the world's first oncolytic virus-based immunotherapy called Teserpaturev, bringing new hope to individuals struggling with a malignant brain tumor known as GBM. Teserpaturev is a genetically engineered herpes simplex virus type 1 (HSV-1) that boasts a unique capability of not only killing the brain tumor cells it infects, but also those that have spread to other parts of the brain. This is achieved by activating a patient's own immune system to fight the tumor.

What are the Challenges Faced by the Progressive Multifocal Leukoencephalopathy Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The market is projected to get significantly affected by the challenging factors such as limited availability and high cost of advanced Progressive Multifocal Leukoencephalopathy Treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth. Furthermore, poor healthcare infrastructure, especially in developing countries, can limit access to Progressive Multifocal Leukoencephalopathy Treatment and the availability of diagnostic and therapeutic options.

Region-Wise Insights

How is the Progressive Multifocal Leukoencephalopathy Treatment Market Turning Out in the South and East Asia Region?

Improvement in healthcare spending propelling growth of the regional markets

The South and East Asia is expected to exhibit the significant growth rate of all regions over the forecast period, with a share of 20% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the progressive multifocal leukoencephalopathy treatment in the region.
South Asia is an emerging market due to the increase in point of care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Progressive Multifocal Leukoencephalopathy Treatment in North America?

Increasing Prevalence of Skin Conditions Shaping Landscape for Progressive Multifocal Leukoencephalopathy Treatment in North America

North America is anticipated to acquire a market share of about 40% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region along with the high healthcare expenditure and a large geriatric population.

The United States of America holds the highest share in the North American market, followed by Canada. Presence of a large number of pharmaceutical companies, which are investing heavily in the development of new, targeted treatments for the condition, high level of healthcare expenditure and the high incidence of PML leading to a large patient population are some of the factors responsible for the growth of the market in the region.

Category-Wise Insights

By Indication, Which Segment is Likely to Account for a Significant Share?

Rising prevalence of HIV infection to push market growth

According to the studies, 38 million people worldwide are currently living with HIV or AIDS. The increasing incidence of HIV infection in many middle- and low-income countries is projected to drive the growth of the market for progressive multifocal leukoencephalopathy treatment over the forecast period.

Favorable reimbursement policies for both HIV and cancer treatment are expected to further drive the growth of the progressive multifocal leukoencephalopathy market over the forecast period.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies to take the lead and drive market growth

According to the FMI analysis, Hospital pharmacy accounts for the largest market share. The requirement for several hospital stays and visits during the progressive multifocal leukoencephalopathy treatment facilitates the growth of this segment. The majority of the serious venous diseases involving the brain are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.

Market Competition

Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.

• In October 2022, Cellevolve Bio, Inc., a company focused on developing and commercializing cell therapies, announced that its Investigational New Drug (IND) application for CE-VST01-JC has been approved by the USA Food and Drug Administration (FDA). CE-VST01-JC is a JC Virus Specific T Cell Therapy that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML) and has received orphan drug designation from the FDA. The safety and effectiveness of CE-VST01-JC will be tested in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 study called ASCEND-JC. The study is expected to enroll up to 60 patients across the USA, Canada, and EU, with the first patient enrollment anticipated in the first half of 2023.
• In June 2021, Teserpaturev received conditional and temporary marketing approval in Japan for the treatment of malignant glioma, based on the results of a Japanese phase 2 clinical trial in patients with GBM. The trial showed that 92% of patients who received Teserpaturev immunotherapy treatment were still alive after one year, which is significantly higher than the typical 15% one-year survival rate in this group of patients receiving standard late-stage brain tumor treatments.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 1,320 million
Market Value in 2033	USD 1,773.97 million
Growth Rate	CAGR of 3% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Treatment, Indication, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	NeoImmuneTech; Inhibikase Therapeutics; Neurimmune; Pfizer Inc.; GSK Plc; Sanofi S.A.; Gilead Sciences Inc.; Allergan Plc.; Novartis AG; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bristol-Myers Squibb Company
Customization	Available Upon Request

Key Segments Profiled in the Progressive Multifocal Leukoencephalopathy Treatment Industry Survey

Treatment:

• Anti-retroviral Therapy
• Antiviral/Anti JCV
• Other Symptomatic

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Indication:

• HIV/AIDS
• Organ Transplantation
• Multiple Sclerosis
• Hematologic Malignancies

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at USD 1,320 million.

How was the market’s historical performance?

The market rose at a 2% CAGR from 2018 to 2022.

What will be the growth rate until 2033?

Until 2033, the market will experience a 3% CAGR.

What will be the market value in 2033?

The market shall reach USD 1,773.97 million in 2033.

What is North America's expected share in 2023?

North America is likely to generate 40% revenue in 2023.